Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.

Emerging microbes & infections - 1 Dec 2024

Wang Qian, Guo Yicheng, Schwanz Logan T, Mellis Ian A, Sun Yiwei, Qu Yiming, Urtecho Guillaume, Valdez Riccardo, Stoneman Emily, Gordon Aubree, Wang Harris H, Ho David D, Liu Lihong

Abstract excerpt

As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1. Compared with other Omicron subvariants, including EG.5.1 and the current predominant JN.1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to COVID-19

Share to Immune Evasion

Share to Neutralization Tests

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 38779718
DOI: 10.1080/22221751.2024.2359004
PMCID: PMC11146261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.PMID 38779718Read ↗

Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.Semantic proximity Read ↗

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75Semantic proximity Read ↗

Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1Semantic proximity Read ↗

Emerging SARS-CoV-2 variants: Why, how, and what's next?Semantic proximity Read ↗

SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants.Semantic proximity Read ↗

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.Semantic proximity Read ↗

Functional and Structural Basis of Omicron BA.3.2.1 SpikeSemantic proximity Read ↗

Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.Semantic proximity Read ↗

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.Semantic proximity Read ↗

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibodySemantic proximity Read ↗

Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2Semantic proximity Read ↗

Evolution and implications of SARS-CoV-2 variants in the post-pandemic eraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.